Loading company…
Omniose is developing bioconjugate vaccines against bacterial threats, including K. pneumoniae.
Founded in 2022 and based in St. Louis, Omniose develops polysaccharide conjugate vaccines using a platform that attaches bacterial sugar antigens to engineered carrier proteins in E. coli. Its vaccine program targets K. pneumoniae. In October 2022, the company received USD 3.6 million in grant funding from the National Institutes of Health. The funds were intended for vaccine development and IND-enabling studies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in